Altogen Biosystems Launches New Nanoparticle-based In Vivo Transfecti...( LAS VEGAS Nov. 3 /- Altogen Biosy...)

LAS VEGAS, Nov. 3 /PRNewswire/ -- Altogen Biosystems (http://www.altogen.com) announced launch of novel Nanoparticle-based transfection reagent for use in laboratories and research facilities for animal testing. Transfection is one of the major laboratory methods used to introduce DNA and RNA molecules into cells and tissues. This technique makes it possible to cross the cellular barriers and deliver a gene or a small interfering RNA (siRNA) into the cells for research or therapeutic purposes.

The company has previously developed lipid- and polymer-based in vivo transfection reagents (http://www.altogen.com/mirna.htm) used for testing pharmaceuticals in animals. Altogen Biosystems recently developed novel nanoparticles biotechnology that allows highly efficient delivery of various biomolecules into animal tissues via systemic administration, as well as intraperitoneal and direct intratumoral injections.

Altogen Biosystems is focusing on commercializing pharma- and bio-technologies, as well as providing custom laboratory research services. The company now offers such innovative services as generation of stably-transformed cell lines in 28-days, as well as gene silencing and RNAi services (http://www.altogen.com/support.htm).

About Altogen Biosystems

Altogen Biosystems is a life sciences company located in Las Vegas, Nevada. The company is dedicated to the engineering, marketing and manufacture of transfection reagents and kits for intracellular and tissue-targeted delivery of biomolecules (http://www.altogen.com).

Altogen Custom Services focus on providing specialized biotechnology and pharmaceutical services, including generation of stable cell lines, gene silencing and RNA Interference (RNAi) services,
'/>"/>